Companies › Inhibrx Biosciences
2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INBRX-109 Tetravalent DR5 agonist antibody | TNFRSF10B | Phase 2 | Conventional Chondrosarcoma; Ewing Sarcoma | Dec 2026 |
| INBRX-106 OX40 receptor agonist antibody | TNFRSF4 | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC); Solid Tumor | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04950075 | INBRX-109 | Phase 2 | Conventional Chondrosarcoma | Oncology | Dec 2026 |
| NCT03715933 | INBRX-109 | Phase 1 | Ewing Sarcoma | Oncology | Dec 2028 |
| NCT06295731 | INBRX-106 | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Dec 2029 |
| NCT04198766 | INBRX-106 | Phase 1 | Solid Tumor | Oncology | Jul 2033 |
Cash of $133m on 2026-06-30; operating cash outflow about $138m a year; runway about 12 months at that burn, to Jun 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Neonc Technologies Dogwood Therapeutics Atossa Therapeutics Curis Oncolytics Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.